Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Advertisement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603807653/en/
Louis Denis, MD, Chief Medical Officer, Byondis
BYON4228 is a potential best-in-class novel mAb that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. By targeting SIRPα and not CD47, BYON4228 offers selective targeting of myeloid cells and avoids disruption of other biologically meaningful CD47-dependent interactions. In preclinical studies, BYON4228 was found to potentiate the tumor killing capacity of tumor-targeting mAbs tested without the toxicity associated with CD47 agents.
'Building on strong preclinical data, we believe that there is broad potential for BYON4228 alone and in combination with tumor-targeting mAbs, checkpoint inhibitors and antibody drug conjugates and other modalities across hematological and solid tumors,' said Louis Denis, MD, Chief Medical Officer, Byondis. 'We look forward to evaluating the results of this trial to support the clinical development of BYON4228 alone and in combination with other agents and to bring a new therapeutic option to patients with high unmet medical need.'
Part 1 of the BYON4228.002 trial will evaluate the safety of BYON4228 alone and in combination to determine the maximum tolerated dose (MTD), or optimal biological dose (OBD) if the MTD is not reached, and recommended combination dose regimen(s) for expansion (RDE(s)). The second part of the trial will evaluate the objective tumor response rate (ORR). The secondary objectives of this trial are safety, pharmacokinetics, immunogenicity and preliminary efficacy. The trial will be conducted at multiple sites across Europe, including the United Kingdom, Belgium and Spain.
About BYON4228
BYON4228 is a novel monoclonal antibody (mAb) from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (NCT05737628) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (NCT06932952).
About Byondis
Driven to improve patients' lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Byondis' broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis' expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis' expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.
The company's headquarters and state-of-the-art R&D and GMP manufacturing facilities are based in Nijmegen, the Netherlands. For more information visit www.byondis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603807653/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
New genetic test can predict if a child will be obese as an adult — before they even turn 5
The future is uncertain — but your kid's waistline as an adult might not be. Scientists have developed a groundbreaking test that can identify children as young as five who are at increased risk of becoming severely obese later in life. The tool could one day help parents and doctors intervene early, setting young people on a healthier path before the pounds start piling on. Advertisement 3 Approximately 1 in 5 US children and adolescents have obesity, according to the Centers for Disease Control and Prevention. Pixel-Shot – That's significant, because America is being weighed down by an obesity epidemic — and it's only expected to get worse without major changes. Today, CDC data shows that more than two in five US adults are obese. By 2050, studies suggest that number could jump to two in three. Obesity greatly increases the risk of serious health problems, many of which are now appearing at younger ages, including diabetes, heart disease, stroke, mental health disorders, cancer and even premature death. Advertisement To build the test, more than 600 scientists from around the globe crunched genetic data from over 5 million people. They used that information to develop ancestry-specific 'polygenic risk scores.' These work like powerful calculators, adding up thousands of gene variants linked to a higher adult body mass index (BMI) to estimate a person's chances of one day becoming obese. 'What makes the score so powerful is its ability to predict, before the age of five, whether a child is likely to develop obesity in adulthood, well before other risk factors start to shape their weight later in childhood,' Roelof Smit, a genetic epidemiologist at the University of Copenhagen, said in a statement. Advertisement 'Intervening at this point can have a huge impact.' 3 People may be able to overcome their higher genetic risk for obesity with lifestyle interventions, research suggests. ÐÑина ÐелÑдий – So far, the tool's performance has been impressive — at least for some groups. Advertisement Among people of European ancestry, the score explained about 17.6% of the risk for developing obesity. 'That's a pretty powerful risk indicator for obesity, but it still leaves open a lot that is unknown,' Dr. Roy Kim, a pediatric endocrinologist not involved in the study, told NBC News. In other words, more than 80% of the risk still comes down to other factors, including where you live, what you eat and the amount you move. Still, the test outperformed the current methods doctors use to estimate a person's future obesity risk, proving to be about twice as effective. 3 There are thousands of genetic variants that can influence a person's chances of becoming obese. LIGHTFIELD STUDIOS – But for people with non-European ancestry, the picture got murkier. In rural Ugandan populations, for example, the score explained just 2.2% of obesity risk. Researchers said the gap likely reflects two key issues: greater genetic variation found in African populations and a lack of diversity in the genetic data used to build the tool. Of the more than 5 million people whose data was used, 71.1% had European ancestry. Just 14.4% had American ancestry, 8.4% East Asian, 4.6% African and only 1.5% South Asian. Advertisement In addition to predicting a person's risk of obesity, the scientists also looked at how genetic predisposition affects a person's response to weight-loss efforts like diet and exercise. They found that people with a higher genetic risk were more likely to benefit from lifestyle changes — but also more likely to regain weight once those efforts stopped. This, the researchers said, challenges the idea that genetic predisposition to obesity can't be overcome, while also highlighting the importance of maintaining healthy habits over time to sustain long-term results.
Washington Post
an hour ago
- Washington Post
Chicago Blackhawks agree with Frank Nazar on a 7-year extension worth $46.13 million
CHICAGO — The Chicago Blackhawks have agreed to terms with forward Frank Nazar on a seven-year extension worth $46.13 million. The team announced the contract Thursday. Nazar will count $6.59 million against the salary cap from when it starts in the 2026-27 NHL season through 2033.
Business Insider
4 hours ago
- Business Insider
ESPN streaming service: Price, plans, and content in the new direct-to-consumer streamer
After a lengthy wait, the brand-new ESPN streaming service has finally arrived. For the first time, all of the flagship ESPN properties will be available in full in one place. The new ESPN streaming service is a one-stop shop for all things ESPN, offering all 12 of ESPN's linear networks in one place. This is a landmark move as more networks begin to launch individual streaming services and double down on their existing DTC (direct-to-consumer) properties. Previously, the cheapest way to live stream the ESPN network directly was through a live TV streaming service (in this case, Sling TV Orange, for $45.99 a month), but the launch of ESPN offers a $29.99 a month solution for sports fans through the enhanced ESPN app. Below, we've outlined everything you need to know about the new ESPN streamer. You can find details on all costs, bundling options, and a limited-time deal. We've also broken down what existing ESPN Plus subscribers can expect. How much is the new ESPN streaming service? The new ESPN streaming service costs anywhere from $11.99 a month to $44.99 a month (discounted to $38.99 a month), depending on which plan or bundle you sign up for. ESPN Select is the cheapest option at $11.99 a month or $119.99 a year, and ESPN Unlimited is the most expensive stand-alone option, with plans starting at $29.99 a month or $299.99 a year. There are four bundle options for ESPN, Disney Plus, and Hulu. Two plans include access to ESPN Unlimited. The basic bundle offers ad-supported Disney Plus and Hulu, starting at $35.99 a month, but users can get their first 12 months for just $29.99 a month. Similarly, the premium bundle offers ad-free Disney Plus and Hulu, and starts at $44.99 a month, but users can get their first 12 months for $38.99 a month. After 12 months, monthly subscriptions will auto-renew at the then-standard rate. These are limited-time deals. The other two plans bundle ad-supported Disney Plus, ad-supported Hulu, and ESPN Select for $16.99 a month or ad-free Disney Plus, ad-free Hulu, and ESPN Select for $26.99 a month. We've only seen ESPN Select, ESPN Unlimited, and the Disney Plus, Hulu, ESPN Unlimited Bundle advertised on the ESPN website, but the other bundles are visible through non-ESPN Disney sites, like Disney Plus and Hulu. You can find a full price breakdown below. Two ESPN bundles, with FOX One and NFL Plus, will launch later this fall. Or, browse directly at ESPN. What are the different ESPN streaming service plans? ESPN has four different subscription options. The two stand-alone ESPN plans are Select and Unlimited. ESPN Select is just ESPN Plus with a new name. It offers the same 32,000 live events, including select coverage from ESPN and ABC networks, but it doesn't have 1:1 live streams of the channels. ESPN Unlimited carries ESPN Select/Plus offerings and live content from ESPN, ESPN2, ESPN3, ESPNU, ESPNews, ESPN Deportes, ESPN on ABC, the SEC Network, SEC Network Plus, the ACC Network, and ACC Network Extra. The currently-available bundle options combine ESPN Unlimited or ESPN Select with ad-supported Disney Plus and Hulu or ad-free Disney Plus and Hulu. Disney Plus unlocks an impressive suite of content from Disney, Pixar, Star Wars, and Marvel, while Hulu carries popular network TV shows, films, and streaming originals. While the stand-alone ESPN Select and Unlimited plans have annual options, which can save consumers money year-over-year compared to paying monthly for 12 months, the bundle options are only available on a month-to-month basis. How to sign up for the new ESPN streaming service It's easy to sign up for the new ESPN streaming service. Just go to the ESPN streaming website and sign up. You can also sign up for the service with the Disney Plus and Hulu bundles via the Disney Plus website. No matter which plan you're trying to sign up for, be it a stand-alone or bundle, you'll be required to make a MyDisney login. If you've ever had a Disney Plus, Hulu, or ESPN Plus account, you'll have a MyDisney login via the email associated with your account. If you haven't subscribed to a Disney-owned streamer in the past, you'll be prompted to make a MyDisney login for the first time. Creating a MyDisney login is free and doesn't require payment. Once you sign in with your new or existing account, you'll be able to see all plan options and select the subscription of your choice. From there, you can input your desired payment method if you don't already have one saved. What about existing ESPN Plus subscribers? Existing ESPN Plus subscribers will be automatically enrolled in ESPN Select, so they don't need to worry about signing up again. Like ESPN Plus, ESPN Select costs $11.99 a month or $119.99 a year, so there will be no change in billing price. The same goes for those currently enrolled in a Disney Plus, Hulu, and ESPN Plus bundle.
